SAP-001
Sponsors
Shanton Pharma Co., Ltd., Shanton Pharma Pte. Ltd.
Conditions
GoutGout, HyperuricemiaHyperuricemia
Phase 1
Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
CompletedNCT03857165
Start: 2018-09-24End: 2019-10-31Updated: 2021-10-14
SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects
CompletedNCT06678581
Start: 2023-05-29End: 2024-01-11Updated: 2024-11-12
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
Active, not recruitingNCT06729853
Start: 2024-04-24End: 2025-04-28Target: 32Updated: 2024-12-11
Phase 2
Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
CompletedNCT04040816
Start: 2019-01-01End: 2020-08-30Updated: 2021-11-05
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
Active, not recruitingNCT05690204
Start: 2022-12-12End: 2025-02-28Updated: 2024-11-14